TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Eidos Therapeutics, Inc. (NASDAQ: EIDX) Investor Investigation Over Possible Wrongdoing Announced

  • Investors who purchased shares of Eidos Therapeutics, Inc. (NASDAQ: EIDX) and currently hold any of those NASDAQ: EIDX shares have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Eidos Therapeutics, Inc.
Security
NASDAQ: EIDX

Summary

An investigation on behalf of current long-term investors in shares of Eidos Therapeutics, Inc. (NASDAQ: EIDX) was announced over potential breaches of fiduciary duties by certain officers and directors at Eidos Therapeutics, Inc.

The investigation by a law firm concerns whether certain Eidos Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Francisco, CA based Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). On April 1, 2019, after the market closed, Eidos Therapeutics, Inc filed a Form with the Securities and Exchange Commission (SEC) announcing that its previously issued financial statements for the first three quarterly periods in the year ended December 31, 2018 could no longer be relied upon.

Shares of Eidos Therapeutics, Inc. (NASDAQ: EIDX) closed on April 8, 2019, at $23.74 per share.

Start Monitoring Your Investments